Ardelyx sells IBSRELA and XPHOZAH, prescription medicines for irritable bowel syndrome and elevated phosphorus in dialysis patients. ARDX reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 4 dark pool prints.
Prices, price targets and earnings estimates for ARDX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARDX is in one of them and how their past ARDX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Ardelyx
Ardelyx is a biopharmaceutical company based in Fremont, California. It sells two prescription medicines, both made from the active ingredient tenapanor. IBSRELA treats adults with irritable bowel syndrome with constipation, and XPHOZAH lowers phosphorus levels in adults with chronic kidney disease who are on dialysis. The company sells these medicines in the United States and is also studying tenapanor for chronic idiopathic constipation.
